CTEV (Claritev) Return-on-Tangible-Asset: -47.74% (As of Mar. 2026)


CTEV Claritev Corp CTEV
53 GF Score
Price $32.90
GF Value $31.34
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Claritev Return-on-Tangible-Asset?

Claritev CTEV +2.75% 53 Return-on-Tangible-Asset is -47.74% as of Mar. 2026. GuruFocus rates CTEV with a GF Score™ of 53/100 and a GF Value™ of $31.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Claritev ranks worse than 85.21% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Claritev's annualized Net Income for the quarter that ended in Mar. 2026 was $-294.2 Mil. Claritev's average total tangible assets for the quarter that ended in Mar. 2026 was $616.4 Mil. Therefore, Claritev's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -47.74%.

The historical rank and industry rank for Claritev's Return-on-Tangible-Asset or its related term are showing as below:

CTEV' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -321.5   Med: -50.79   Max: 20.13
Current: -47.64

During the past 8 years, Claritev's highest Return-on-Tangible-Asset was 20.13%. The lowest was -321.50%. And the median was -50.79%.

CTEV's Return-on-Tangible-Asset is ranked worse than
85.21% of 683 companies
in the Healthcare Providers & Services industry
Industry Median: 2.43 vs CTEV: -47.64

Claritev  (NYSE:CTEV) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Claritev Return-on-Tangible-Asset Related Terms


Claritev Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Claritev's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Claritev Return-on-Tangible-Asset Chart

Claritev Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial 20.13 -88.28 -14.93 -321.50 -50.79

Claritev Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.70 -43.37 -45.25 -52.97 -47.74

CTEV vs MDRX, EVH, PHR: Return-on-Tangible-Asset Comparison

For the Health Information Services subindustry, Claritev's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Claritev Return-on-Tangible-Asset vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Claritev's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Claritev's Return-on-Tangible-Asset falls into.


CTEV
53GF Score
Claritev Corp CTEV
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Claritev Return-on-Tangible-Asset Calculation

Claritev's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-284.282/( (521.364+598.001)/ 2 )
=-284.282/559.6825
=-50.79 %

Claritev's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-294.24/( (598.001+634.75)/ 2 )
=-294.24/616.3755
=-47.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -47.74% mean?
Claritev (CTEV) has a Return-on-Tangible-Asset of -47.74% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Claritev and its competitors. According to the industry distribution chart, Claritev ranks #582 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 85.2%.
Is Claritev's Return-on-Tangible-Asset too high?
Claritev's current Return-on-Tangible-Asset is -47.74%. Based on the distribution chart, Claritev ranks #582 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Claritev has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Claritev's Return-on-Tangible-Asset compare to MDRX and EVH?
According to the Healthcare Providers & Services industry distribution chart, Claritev ranks #582 out of 683 companies for Return-on-Tangible-Asset. This places Claritev in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Claritev and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Claritev's current Return-on-Tangible-Asset is -47.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Claritev stock overvalued right now?
Based on GuruFocus' analysis, Claritev (CTEV) is currently considered Fairly Valued. The stock's GF Value™ is $31.34, compared to a current price of $32.90 — trading 5% above its estimated fair value. The current Return-on-Tangible-Asset is -47.74%. Claritev's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Claritev (CTEV), the current Return-on-Tangible-Asset is -47.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Claritev (CTEV) Overvalued in 2026?

Based on GuruFocus' analysis, Claritev stock appears to be overvalued. The current stock price of $32.90 is trading 5% above its estimated GF Value™ of $31.34. GuruFocus considers Claritev to be Fairly Valued.

Key valuation signals for CTEV:

  • Return-on-Tangible-Asset: -47.74%
  • GF Value™: $31.34 vs. price of $32.90 (5% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the CTEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Claritev Business Description

Address 7900 Tysons One Place, Suite 400, McLean, VA, USA, 22102
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
53GF Score

Get the complete analysis for CTEV

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.90
Price
$31.34
GF Value